AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29794277
Drug: IV morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV morphine (MOR) 0.1 mg/kg
Trial: 18240258
Drug: Anti-TNFα treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TNFα treatment in PsA
Trial: 18240258
Drug: Anti-TNFα treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TNFα treatment in AS
Trial: 18240258
Drug: Anti-TNFα treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TNFα treatment in RA
Trial: 12442933
Drug: Cisatracurium (intubation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisatracurium (intubation dose 0.1 mg kg(‐1))
Trial: 12442933
Drug: Atracurium (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium (0.5 mg kg(‐1))
Trial: 12442933
Drug: Cisatracurium (effective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisatracurium (effective dose 0.05 mg kg(‐1))
Trial: 12442933
Drug: Cisatracurium (repeat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisatracurium (repeat dose 0.02 mg kg(‐1))
Trial: 10350246
Drug: High-dose tirilazad
RxNorm normalized name: TIRILAZAD
DrugBank: Tirilazad (DB13050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose tirilazad mesylate (15 mg/kg/day)
Trial: 6803633
Drug: Control exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control exercise challenges (no treatment)
Trial: 22931315
Drug: Clopidogrel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (75 mg daily) + Aspirin (325 mg daily)
Trial: 12860867
Drug: Comparison between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison between atorvastatin and simvastatin
Trial: 10365900
Drug: Erythromycin in
RxNorm normalized name: erythromycin Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin in normoglycaemia (200 mg intravenously)
Trial: 10365900
Drug: Erythromycin in
RxNorm normalized name: erythromycin Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin in hyperglycaemia (200 mg intravenously)
Trial: 10150850
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy and long-term laser treatment for capsular glaucoma
Trial: 2132565
Drug: Folinic acid
RxNorm normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Folinic acid (leucovorin) supplementation given orally 4 hours after weekly low dose methotrexate administration
Trial: 6110536
Drug: Active TBE-vaccination
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active TBE-vaccination (purified TBE vaccine)
Trial: 27518188
Drug: EVA Park
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EVA Park intervention (daily language stimulation sessions for 5 weeks)
Trial: 20643015
Drug: Levobupivacaine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine (5 mL of levobupivacaine hydrochloride, 25 mg/10 mL) soaked Merocele packs
Trial: 15777102
Drug: Oxymorphone IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxymorphone IR (all doses)
Trial: 10959382
Drug: Losartan (Ocsaar)
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Losartan (Ocsaar) 50 mg daily, increased to 100 mg if necessary
Trial: 9000839
Drug: Doxazosin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin therapy for 3 years
Trial: 7280947
Drug: Parenteral cefamandole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral cefamandole
Trial: 7280947
Drug: Parenteral penicillin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral penicillin, gentamicin and clindamycin
Trial: 26078579
Drug: PUFA therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUFA therapy (50 mL PUFA with 1:1 ratio of EHA and DHA added to daily diet)
Trial: 26078579
Drug: PUFA therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUFA therapy
Trial: 23566237
Drug: Autologous fibroblast
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous fibroblast treatment
Trial: 19623052
Drug: Daily exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily exercise training session for 20 mins/day using a bedside cycle ergometer
Trial: 16786420
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist with low-dose hCG protocol (hCGP)
Trial: 16786420
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist with no low-dose hCG protocol (NhCGP)
Trial: 16786420
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (buserelin) long protocol (LP)
Trial: 15475021
Drug: Intensity effect
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensity effect on insulin
Trial: 11402958
Drug: iohexol 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iohexol 0.6 ml/kg (G1)
Trial: 11402958
Drug: iohexol 1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iohexol 1.2 ml/kg (G2)
Trial: 11402958
Drug: sodium and
RxNorm normalized name: Sodium and/or sodium compound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sodium and meglumine diatrizoate 58% 0.6 ml/kg (G3)
Trial: 11402958
Drug: sodium and
RxNorm normalized name: Sodium and/or sodium compound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sodium and meglumine diatrizoate 58% 1.2 ml/kg (G4)
Trial: 9114762
Drug: class I
RxNorm normalized name: HLA class I antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: class I drugs
Trial: 9114762
Drug: class I
RxNorm normalized name: HLA class I antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: class I drugs with beta blockers
Trial: 8029263
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg caffeine + 2 mg nicotine polacrilex
Trial: 8029263
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg caffeine + 4 mg nicotine polacrilex
Trial: 20949349
Drug: Norepinephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine infusion at target MAP of 75 mmHg
Trial: 20949349
Drug: Norepinephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine infusion at target MAP of 60 mmHg
Trial: 20949349
Drug: Norepinephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine infusion at target MAP of 90 mmHg
Trial: 18187617
Drug: Nicotinic acid
RxNorm normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotinic acid (NA) 1 g 60 min before, and 0.5 g 60 and 180 min after sprint 1
Trial: 16303987
Drug: Medication utilization
RxNorm normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication utilization patterns in patients with BPD
Trial: 12745514
Drug: Metacholine (MCh;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metacholine (MCh; 2 and 4 mg/min) and sodium nitroprusside (SNP; 5 and 10 mg/min)
Trial: 11187922
Drug: American therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: American therapy template with two post-remission intensification modules
Trial: 11187922
Drug: Intrathecal methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intrathecal methotrexate injections
Trial: 11187922
Drug: Age, sex,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Age, sex, and white count >50 x 10(9)/l
Trial: 8884642
Drug: Scaling and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scaling and root planing plus application of 2% minocycline gel (S + Min)
Trial: 8884642
Drug: Scaling and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scaling and root planing plus application of 25% metronidazole gel (S + Met)
Trial: 29059186
Drug: DEC and
RxNorm normalized name: insulin degludec and liraglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEC and albendazole (single oral dose, repeated annually or semi-annually)
Trial: 26943607
Drug: S100 levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S100 levels <123 pg mL-1 on PD1
Trial: 25726215
Drug: Prescription at
RxNorm normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription at home (PRES)
Trial: 22994049
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive pretreatment (OCP), n = 53
Trial: 19923550
Drug: IV bapineuzumab
RxNorm normalized name: Bapineuzumab
DrugBank: Bapineuzumab (DB11715)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV bapineuzumab (0.15, 0.5, 1.0, or 2.0 mg/kg)
Trial: 17525395
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of uric acid (UA)
Trial: 17525395
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg of uric acid (UA)
Trial: 15217656
Drug: 0.04 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.04 mg/kg of midazolam IV 20 minutes preoperatively
Trial: 9736008
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) of residual symptoms supplemented by lifestyle modification and well-being therapy
Trial: 2571295
Drug: Beta‐adrenergic blockers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta‐adrenergic blockers
Trial: 2571295
Drug: Captopril (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (100 mg) with Hydrochlorothiazide (25 mg)
Trial: 2571295
Drug: Pindolol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol (10 mg) with Clopamide (5 mg)
Trial: 180192
Drug: Topical interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical interferon inducer (CP 20961)
Trial: 180192
Drug: Drug vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug vehicle (polysorbate-80 in glycerol and saline)
Trial: 180192
Drug: Oral lactose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral lactose
Trial: 27940063
Drug: Wireless pill
RxNorm normalized name: careless weed pollen extract
DrugBank: Amaranthus palmeri pollen (DB10459)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wireless pill bottle use alone (control)
Trial: 21175995
Drug: Rikkunshito (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rikkunshito (7.5 g day(-1) for 2 weeks)
Trial: 10661479
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human growth hormone (rhGH) 4 IU/m2
Trial: 10661479
Drug: placebo injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo injections
Trial: 8350309
Drug: Supplementary clinical
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplementary clinical instruction by general internal medicine physicians
Trial: 3513642
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg mefloquine, 1.5 g sulfadoxine, 75 mg pyrimethamine (MSP)
Trial: 3513642
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg quinine 8‐hourly for 3 days and 500 mg tetracycline 8‐hourly for 7 days (Q3T7)
Trial: 3513642
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg quinine 8‐hourly for 7 days and 500 mg tetracycline 8‐hourly for 7 days (Q7T7)
Trial: 31925727
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment with diet and exercise (Control)
Trial: 27523186
Drug: Bimuno-galactooligosaccharide (B-GOS)
RxNorm normalized name: fructooligosaccharide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimuno-galactooligosaccharide (B-GOS) 5.5 g/d for 3 weeks
Trial: 24062227
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 30 mg/kg TXA on induction of surgery (one shot [OS] group)
Trial: 24062227
Drug: Loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose of 10 mg/kg TXA followed by continuous infusion of 2 mg/kg per hour for 20 hours (one day [OD] group)
Trial: 20104197
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment plus lower‐molecular weight heparin treatment (LT group)
Trial: 18557664
Drug: 400 microg
RxNorm normalized name: Fentanyl 400 microgram buccal film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 microg B(12) + 2 mg folic acid + 25 mg B(6) per day
Trial: 15949922
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg sodium valproate
Trial: 15949922
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg lithium
Trial: 10223267
Drug: C+E (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C+E (375 mg caffeine and 75 mg ephedrine)
Trial: 31911072
Drug: Dual continuous
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual continuous theta burst stimulation (cTBS) over left inferior frontal gyrus (IFG‐L) and right inferior parietal gyrus (IPL‐R)
Trial: 31911072
Drug: Single site
RxNorm normalized name: Seprafilm Single Site
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single site IFG‐L cTBS
Trial: 21675876
Drug: Smoking cessation
RxNorm normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking cessation program with exercise (nicotine replacement therapy, behavioral counseling, exercise prescription)
Trial: 19131322
Drug: Self-etching adhesive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-etching adhesive treatment
Trial: 15673999
Drug: Moderate dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate dose multivitamin/mineral supplement
Trial: 11201778
Drug: Topical tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Topical tobramycin 0.3%
Trial: 9010042
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy comprising cyclophosphamide, doxorubicin and oral ftorafur (CAFt) with tamoxifen
Trial: 9010042
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy comprising cyclophosphamide, doxorubicin and oral ftorafur (CAFt) without tamoxifen
Trial: 3113222
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of rt-PA
Trial: 26836245
Drug: 10 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 μg vaginal E2 softgel capsules
Trial: 24627787
Drug: Olanzapine (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (both doses)
Trial: 20070250
Drug: Atorvastatin 80
RxNorm normalized name: atorvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80 mg daily for 3 months (statin‐treated, ST n=39)
Trial: 20070250
Drug: Previous therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Previous therapy (statin‐free, SF)
Trial: 10392878
Drug: Transdermal patches
RxNorm normalized name: MENTHOL 0.3 g in 100 TOPICAL PATCH [Aroamas Cot Nicotine Transdermal Patches]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal patches of estradiol‐17beta
Trial: 28905172
Drug: Extended-duration betrixaban
RxNorm normalized name: Betrixaban
DrugBank: Betrixaban (DB12364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extended-duration betrixaban (80 mg once daily for 35-42 days)
Trial: 28905172
Drug: Standard-of-care enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care enoxaparin (40 mg once daily for 10±4 days)
Trial: 25752889
Drug: THC 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC 0.75 mg
Trial: 25752889
Drug: THC pharmacokinetics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC pharmacokinetics
Trial: 21333015
Drug: School-based psychological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: School-based psychological intervention (cognitive-behavioural models); 11 weekly sessions and 3 booster sessions.
Trial: 9385238
Drug: Operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative treatment (proximal realignment procedures)
Trial: 7957511
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg pirsidomine
Trial: 7957511
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg pirsidomine
Trial: 2890307
Drug: Targeted medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted medication plus psychosocial intervention
Trial: 23964932
Drug: Vedolizumab (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vedolizumab (300 mg) intravenously at weeks 0 and 2
Trial: 20615906
Drug: Citrate-enriched dialysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citrate-enriched dialysate (3 mEq/L)
Trial: 18447215
Drug: Point sticking
RxNorm normalized name: Joint Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Point sticking therapy (Sanleng, Ezhu, Zhi Nanxing, Bingpian applied to Qihai, Guanyuan, and Ashi points)
Trial: 18447215
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of Rupixiao (control group)
Trial: 18447215
Drug: Point sticking
RxNorm normalized name: Joint Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Point sticking therapy
Trial: 16324916
Drug: Ephedrine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine (25 mg TID) plus caffeine (200 mg TID)
Trial: 16324916
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Pioglitazone + Ephedrine + Caffeine)
Trial: 4017422
Drug: Intravenous felodipine
RxNorm normalized name: Felodipine
DrugBank: Felodipine (DB01023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous felodipine (2.5 mg infusion over 30 minutes)
Trial: 4017422
Drug: Oral felodipine
RxNorm normalized name: Felodipine
DrugBank: Felodipine (DB01023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral felodipine (27.5 mg solution)
Trial: 12473552
Drug: Intravenous platelet
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous platelet GP IIb/IIIa inhibitors
Trial: 2136871
Drug: Alprazolam (4-9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (4-9 mg)
Trial: 2136871
Drug: Amitriptyline (100-225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (100-225 mg)
Trial: 6146371
Drug: Anxiolytic medication
RxNorm normalized name: ANXIOLYTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anxiolytic medication
Trial: 69290
Drug: Diamorphine and
RxNorm normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diamorphine and Morphine
Trial: 29658257
Drug: Ningmitai Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ningmitai Capsules (NMT)
Trial: 29658257
Drug: Ningmitai Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ningmitai Capsules + Doxycycline hydrochloride (NMT+DH)
Trial: 24655693
Drug: 6-week clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-week clopidogrel therapy
Trial: 24655693
Drug: 6-month clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-month clopidogrel therapy
Trial: 21288215
Drug: Propofol 1.5-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 1.5-2 mg/kg
Trial: 19635155
Drug: Postoperative IABP
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative IABP therapy
Trial: 12890209
Drug: Itraconazole pulse
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole pulse therapy for 2 months and amorolfine 5% solution nail lacquer for 6 months
Trial: 12890209
Drug: Itraconazole monotherapy
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole monotherapy (three pulses)
Trial: 10225576
Drug: Cefotaxime 1
RxNorm normalized name: cefotaxime 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime 1 g
Trial: 2228842
Drug: Five day
RxNorm normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five day oral course of co-amoxyclav (amoxycillin plus clavulanic acid)